Abstract
Health equity is a growing concern for global policymakers. Conventional cost-effectiveness analysis (CEA) primarily focuses on average health outcomes, often neglecting distributional impacts on health equity. While Distributional Cost-Effectiveness Analysis (DCEA) can quantify these impacts, its requirement for detailed subgroup data often makes it impractical. This paper introduces Aggregate DCEA (A-DCEA) as a pragmatic alternative that utilizes aggregated data to evaluate the equity implications of healthcare interventions. A-DCEA provides a valuable and accessible method for promoting health equity in decision-making, particularly when data limitations preclude a full DCEA.
Introduction: The Equity Gap in Economic Evaluation
Healthcare policymakers face the constant challenge of allocating limited resources efficiently. Traditionally, they rely on Cost-Effectiveness Analysis (CEA), which measures the average health gain (e.g., cost per quality-adjusted life year, or QALY) across a population. However, CEA's focus on aggregate efficiency ignores the distribution of those benefits. An intervention might be highly cost-effective on average but disproportionately benefit advantaged groups, inadvertently widening existing health disparities.
Distributional Cost-Effectiveness Analysis (DCEA) was developed to bridge this gap. However, conducting a full DCEA requires massive amounts of granular data—such as costs, benefits, and disease risks stratified by socioeconomic status or ethnicity—which is rarely available for rare diseases or in low- and middle-income countries. This creates a need for a middle-ground solution: Aggregate DCEA (A-DCEA).
Methodology: The A-DCEA Workflow
A-DCEA takes a top-down approach, starting with the average benefits identified in a standard CEA and distributing them across socioeconomic groups using known social patterns in healthcare usage. The paper outlines a clear six-step workflow for its implementation:
- Initial Health Distribution: Estimate baseline health across population groups using quality-adjusted life expectancy (QALE).
- Health Opportunity Costs: Distribute the health benefits forgone by reallocating resources to the new intervention.
- Net Health Benefit (NHB): Calculate the NHB for each group by subtracting opportunity costs from health gains.
- Post-Intervention Distribution: Determine the new health distribution by adding the NHB to the baseline.
- Calculate EDEH: Use an inequality index (like the Atkinson or Kolm index) to calculate the Equally Distributed Equivalent Health (EDEH) for pre- and post-intervention states.
- Population Equity Impact: Compare pre- and post-intervention EDEHs to determine if the intervention reduces or exacerbates health inequality.
Practical Application and Insights
A-DCEA demonstrates that the choice between equity and efficiency is not necessarily a zero-sum game. By using tools like the health equity impact plane and social welfare indices, policymakers can quantitatively weigh societal preferences for reducing inequality alongside traditional cost-efficiency.
This approach is vital for evaluating emerging technologies, such as precision breast cancer screening or genomic newborn screening. These innovations risk widening the health gap if socioeconomic access disparities are not factored into their economic evaluations. A-DCEA provides a "good enough" approximation to prevent policies from blindly exacerbating inequality when granular data is missing.
Evidence of Viability
The viability of A-DCEA is supported by its successful application in several recent studies. For example, an evaluation of familial hypercholesterolemia (FH) screening used A-DCEA to show that screening programs can be more favorable if they proportionally benefit the most deprived groups. To date, A-DCEA has also been applied to evaluations for diabetic macular edema and non-small cell lung cancer, indicating its potential as a versatile tool in health economics.
Limitations and Future Work
While pragmatic, A-DCEA involves methodological trade-offs. It often assumes equal access and equal benefit across all groups, which may lead to overestimating an intervention's ability to reduce inequality, as disadvantaged groups often face higher systemic barriers and more comorbidities. Additionally, the model typically ignores statistical uncertainty surrounding baseline health distributions and opportunity costs.
Despite these limitations, the wider adoption of A-DCEA—particularly in data-scarce environments—could ensure that equity becomes a cornerstone of health intervention assessments. Integrating this tool into standard practice will lead to more informed policies that balance efficient resource use with the reduction of health inequities.
Summary updated